He PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010, 116(22):4578587. Derheimer FA, Kastan MB: Numerous roles of ATM in monitoring and sustaining DNA integrity. FEBS Lett 2010, 584(17):3675681. Bensimon A, Aebersold R, Shiloh Y: Beyond ATM: the protein kinase landscape of your DNA damage response. FEBS Lett 2011, 585(11):1625639. Shiloh Y: Ataxia-telangiectasia plus the Nijmegen breakage syndrome: related disorders but genes apart. Annu Rev Genet 1997, 31:63562. Lavin MF: Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008, 9(10):75969. Shuen AY, Foulkes WD: Inherited mutations in breast cancer genes isk and response. J Mammary Gland Biol Neoplasia 2011, 16(1):35. Prodosmo A, De Amicis A, NisticC, Gabriele M, Di Rocco G, Monteonofrio L, Piane M, Cundari E, Chessa L, Soddu S: p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes. J Clin Invest 2013, 123(3):1335342. Biton S, Dar I, Mittelman L, Pereg Y, Barzilai A, Shiloh Y: Nuclear ataxia-telangiectasia mutated (ATM) mediates the cellular response to DNA double strand breaks in human neuron-like cells. J Biol Chem 2006, 281(25):174827491. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR: Molecular profiling of breast cancer cell lines defines relevant tumor models and gives a resource for cancer gene discovery.Canakinumab PLoS 1 2009, 4(7):e6146.Etokimab Shiloh Y: The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 2006, 31(7):40210. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT: The combined status of ATM and p53 hyperlink tumor improvement with therapeutic response. Genes Dev 2009, 23(16):1895909. Knappskog S, Chrisanthar R, L kevik E, Anker G, tenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, L ning PE: Low expression levels of ATM may well substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res 2012, 14(2):R47. Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, Van’t Veer LJ: Cross-platform pathway-based evaluation identifies markers of response towards the PARP inhibitor olaparib.PMID:24631563 Breast Cancer Res Treat 2012, 135(2):50517. doi: ten.1007/s10549-012-2188-0. Epub 2012 Aug 9.Gilardini Montani et al. Journal of Experimental Clinical Cancer Investigation 2013, 32:95 http://www.jeccr/content/32/1/Page ten of30. Mendeleyev J, Kirsten E, Hakam A, Buki KG, Kun E: Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction for the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem Pharmacol 1995, 50(five):70514. 31. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH: Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012, 18(six):1655662. 32. Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Prepared DB, Soni NB, Ladror US, Xu AJ, Iyer R, Harlan JE, Solomon LR, Donawho CK, Penning TD, Johnson EF, Shoemaker AR: Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012, 18(two):51023.doi:10.1186/1756-9966-32-9.
